CDT Equity (CDT) Competitors

CDT Equity logo
$0.27 -0.08 (-22.13%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$0.27 +0.00 (+1.83%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CDT vs. HEPA, ASLN, NMTR, BPTSY, and ARTL

Should you buy CDT Equity stock or one of its competitors? CDT Equity's main competitors and comparable companies include Hepion Pharmaceuticals (HEPA), ASLAN Pharmaceuticals (ASLN), 9 Meters Biopharma (NMTR), Biophytis (BPTSY), and Artelo Biosciences (ARTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CDT Equity compare to Hepion Pharmaceuticals?

CDT Equity (NASDAQ:CDT) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

CDT Equity's return on equity of -40.99% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CDT EquityN/A -40.99% -33.11%
Hepion Pharmaceuticals N/A -812.56%-207.31%

CDT Equity has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CDT EquityN/AN/A-$39.22M-$32.16 thousandN/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

In the previous week, CDT Equity had 3 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 3.00 beat CDT Equity's score of 0.39 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
CDT Equity Neutral
Hepion Pharmaceuticals Very Positive

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 0.0% of CDT Equity shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

CDT Equity beats Hepion Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does CDT Equity compare to ASLAN Pharmaceuticals?

CDT Equity (NASDAQ:CDT) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

CDT Equity has higher earnings, but lower revenue than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CDT EquityN/AN/A-$39.22M-$32.16 thousandN/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

In the previous week, CDT Equity had 4 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for ASLAN Pharmaceuticals. CDT Equity's average media sentiment score of 0.39 beat ASLAN Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company Overall Sentiment
CDT Equity Neutral
ASLAN Pharmaceuticals Neutral

CDT Equity has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CDT Equity's return on equity of -40.99% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CDT EquityN/A -40.99% -33.11%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 0.0% of CDT Equity shares are held by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CDT Equity beats ASLAN Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does CDT Equity compare to 9 Meters Biopharma?

CDT Equity (NASDAQ:CDT) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

CDT Equity's return on equity of -40.99% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CDT EquityN/A -40.99% -33.11%
9 Meters Biopharma N/A -584.97%-159.45%

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 0.0% of CDT Equity shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CDT Equity had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for 9 Meters Biopharma. CDT Equity's average media sentiment score of 0.39 beat 9 Meters Biopharma's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company Overall Sentiment
CDT Equity Neutral
9 Meters Biopharma Neutral

CDT Equity has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

CDT Equity is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CDT EquityN/AN/A-$39.22M-$32.16 thousandN/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Given 9 Meters Biopharma's higher probable upside, analysts plainly believe 9 Meters Biopharma is more favorable than CDT Equity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

CDT Equity beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks.

How does CDT Equity compare to Biophytis?

CDT Equity (NASDAQ:CDT) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CDT EquityN/AN/A-$39.22M-$32.16 thousandN/A
BiophytisN/AN/A-$18.43MN/AN/A

Biophytis' return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
CDT EquityN/A -40.99% -33.11%
Biophytis N/A N/A N/A

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 0.0% of CDT Equity shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CDT Equity had 3 more articles in the media than Biophytis. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Biophytis. CDT Equity's average media sentiment score of 0.39 beat Biophytis' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CDT Equity
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biophytis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CDT Equity has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

Summary

Biophytis beats CDT Equity on 5 of the 9 factors compared between the two stocks.

How does CDT Equity compare to Artelo Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Artelo Biosciences has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CDT Equity's return on equity of -40.99% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -272.21% -159.13%
CDT Equity N/A -40.99%-33.11%

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 0.0% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CDT Equity had 4 more articles in the media than Artelo Biosciences. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 1.50 beat CDT Equity's score of 0.39 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Artelo Biosciences Very Positive
CDT Equity Neutral

Artelo Biosciences is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$47.20N/A
CDT EquityN/AN/A-$39.22M-$32.16 thousandN/A

Summary

CDT Equity beats Artelo Biosciences on 5 of the 9 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDT vs. The Competition

MetricCDT EquityPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$350K$13.35B$7.59B$11.70B
Dividend YieldN/A2.60%2.48%4.65%
P/E RatioN/A26.9031.9926.76
Price / SalesN/A7.098.405.53
Price / CashN/A15.5320.7221.66
Price / Book0.005.304.423.65
Net Income-$39.22M$2.87B$3.51B$394.00M
7 Day Performance-33.29%-5.14%-5.44%-5.74%
1 Month Performance-91.60%-7.77%-8.62%-9.54%
1 Year Performance-100.00%-6.74%-1.31%-6.71%

CDT Equity Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDT
CDT Equity
0.7763 of 5 stars
$0.27
-22.1%
N/A-100.0%$350KN/AN/A4
HEPA
Hepion Pharmaceuticals
N/A$0.12
+13.6%
N/A+39.9%$1.32MN/AN/A20
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12MN/A30
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
BPTSY
Biophytis
N/A$0.40
flat
N/AN/A$938KN/AN/A30

Related Companies and Tools


This page (NASDAQ:CDT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners